vTv Therapeutics Inc.
10/25/2024 | Press release | Distributed by Public on 10/25/2024 14:30
Termination of Material Agreement Form 8 K
Item 1.02 Termination of a Material Definitive Agreement
On October 22, 2024, vTv Therapeutics LLC ("vTv LLC"), a controlled subsidiary of vTv Therapeutics Inc. (the "Company"), received notice from OnKure Therapeutics, formerly Reneo Pharmaceuticals, Inc. ("OnKure"), of their intent to terminate the License Agreement between vTv LLC and Reneo Pharmaceuticals, Inc., dated December 21, 2017, as amended December 20, 2021 (the "Agreement"). Under the Agreement, the Company had granted OnKure an exclusive, worldwide license to intellectual property pertaining to the Company's peroxisome proliferator-activated receptor delta (ppar-δ) agonist program. In its notice, OnKure indicated that it had decided to discontinue development of the program. Under the Agreement, the termination will become effective as of January 20, 2025.
vTv Therapeutics Inc. published this content on October 25, 2024, and is solely responsible for the information contained herein. Distributed via EDGAR on October 25, 2024 at 20:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]